·2572-
[5][6][7][8]
刘晖杰，等
全运科，陈天法，梅延兰，等.顺铂加足叶乙试联合化疗治疗恶性体腔积减[J].中华肿缩杂志，1995，17(3)：198
李鼎九，胡自省.肿瘤热疗学[M].郑州：河南医科大学出版社， 199532 120
黄培，周菊英.热疗在肿瘤治疗中的研究选展[J].现代肿瘤医学,2010,18(7)：14601461.
Mayer RE, Brann RD, Rosmer GL,et al. Local 42 degrees C hyper-thermia improves vascular conductance of the RS3230Ae rat mam-
右丙亚胺对复发平滑肌肉瘤患者化疗的心脏保护作用研究 mary adenoearcinoma during sodium nitroprusaide infusion[ J]. Ra-diat Res,2000,154(2) :196.
贾英杰，陈立伟，陈军，等.康来特与顺铂胸腔注射联合局部热
19]
疗治疗恶性胸水的临床观察(J].辽宁中医杂态，2007，34(5： 607608.
[10]
虞喜紊，李新姆，周建架，等，腹腔化疗联合践部透热全身热疗治疗恶性腹水[J].实用肿瘤学杂志，2007,21(2)：132.
（编校：张西敏）
右丙亚胺对复发平滑肌肉瘤患者化疗的心脏保护作用研究刘晖杰，许华，吴悠扬
Protectiveeffectofdexrazoxaneonanthracyclinescardio-toxicityofrelapsesarcoma
patients freated with chemotherapy Liu Huijie,Xu Hua,Wu Youyang
Department of Oncology,Xiangyang Central Hospital,Hubei Xiangyang 441021,China.
[ Abstract] Objective:To observe the protective effect of dexrazoxane( DEX) on cardio toxicity induced by an-thracyclines treated for the relapse sarcoma of smooth muscle. Methods: All 29 relapse sarcoma patients of smooth muscle were randomly divided into DEX group and control group. Both groups received 5 cycles chemotherapy therapy regimen based on anthracyclines. DEX group plus dexrazoxane (DEX: EPI = 10: 1) since the first use of anthracy-clines, Cardiofunction was evaluated by monitoring cTnT and LEVF during every periods and statistic incidence rate of CHF and observation the non cardiotoxicity and clinical effect were observed, Results: There was no significant difference between two groups in age,weight,ECOG and stages. cTnT had obviously increased from the first cycle of EPI treatment and reach maximum at the end of treatment, cTnT had still maintained at a relatively high level until two years after treatment. However cTnT had maintained at a relatively low level in DEX group during treatment and after treatment. The difference between the two groups was significant( P < 0. 05). The difference of the LEVF and non cardiotoxicity in two groups was not significant(P >0. 05),. Conclusion: EPI causes obviously cardiotoxici-ty since the first usage,but EPI plus DEX could decrease this cardiotoxicity.
[Key words] dexrazoxane;relapse sarcoma of smooth muscle;anthracyclines cardioprotection
Modem Oncology 2013,21(11) :2572 2574
【摘要】
目的：观察右丙亚胺(dexrazoxane,DEX)对平滑肌肉瘤复发患者接受蕙环类药物辅助化疗所致心脏
毒副反应的保护作用。方法：将29例复发平滑肌肉瘤患者随机分成治疗组(DEX组)和对照组。两组惠者均接受以总环类药物为基础的辅助化疗5个周期，治疗组在使用总环类药物化疗的基础上加用右丙亚胺（右丙亚胺：表柔比星=10:1)，在第--次应用葱环类药物时即给予右丙亚胺。监测各时期心肌肌钙蛋白(cTnT)和左心室射血分数(LEVF)，统计临床心功能不全的发生率以进行心脏功能评估，同时观察治疗的非心脏毒副反应及疗效。结果：两组患者在年龄、体重、ECOG评分等方面没有统计学差异（P>0.05）。从表柔比星(EPI)治疗的第一个周期开始cTnT明显上升，到治疗结束时达到最高，直到治疗后2年仍然维持在较高水平。加用DEX组（即治疗组)在治疗期间及治疗后cTnT水平都较低，两组比较差异有显著性(P<0.05）。而 LEVF在两组的各个治疗阶段水平都没有统计学差异（P>0.05）。两组的非心脏毒副反应没有差异。结论： EPI从第一次应用时对心脏便产生了明显的毒副反应，加用DEX后可以降低这种心脏毒副反应。
【收稿目期】【作者单位】【作者简介】【通讯作者】
2013 04 28
襄阳市中心医院肿瘤科，湖北襄阳441021
刘晖杰（1977-），女，潮北随州人，主治医师，硕士，主要从事肿瘤放化疗的研究。E-mail：xfhuahua163.0om 许华(1979-），男，湖北保康人，硕士，审计师，主要从事医院管理工作。